Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB2 | O60825 | 1/20 | 0.61 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.61 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086627 | 0.87 | PFKFB2 (0.59) | PFKFB2PFKFB1PFKFB3IMPDH2IMPDH1 | |
| SCHEMBL2006656 | 0.82 | IMPDH2 (0.56) | PFKFB2PFKFB1PFKFB3IMPDH2IMPDH1 | |
| SCHEMBL6090436 | 0.80 | IMPDH2 (0.70) | PFKFB2PFKFB1PFKFB3IMPDH2MEN1 | |
| SCHEMBL1778261 | 0.78 | GPR84 (0.57) | PFKFB2PFKFB1PFKFB3IMPDH2IMPDH1 | |
| SCHEMBL6087078 | 0.77 | PFKFB2 (0.50) | PFKFB2PFKFB1PFKFB3IMPDH2IMPDH1 | |
| SCHEMBL21856775 | 0.77 | PFKFB1 (1.00) | PFKFB2PFKFB1PFKFB3IMPDH2MEN1 | |
| SCHEMBL2736715 | 0.75 | PFKFB2 (0.50) | PFKFB2PFKFB1PFKFB3IMPDH2IMPDH1 | |
| SCHEMBL19280740 | 0.74 | CYP19A1 (0.54) | MEN1KMT2AESR1ESR2 | |
| SCHEMBL30473827 | 0.74 | CYP19A1 (0.54) | MEN1KMT2AESR1ESR2 | |
| SCHEMBL5857843 | 0.73 | IMPDH2 (0.81) | IMPDH2IMPDH1MEN1KMT2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | claimed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | claimed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | claimed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | PFKFB2 1285/4885PFKFB1 799/4885PFKFB3 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.